November 05, 2018
1 min read
Save

Lipocine completes enrollment for study of oral NASH treatment

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Lipocine completed patient enrollment in a proof-of-concept clinical study of LPCN 1144 for the treatment of nonalcoholic steatohepatitis, according to a press release.

The study will assess liver fat changes in men with hypogonadism and fatty liver who are at risk for developing NASH using magnetic resonance imaging-proton density fat fraction after treatment with LPCN 1144, an oral prodrug of bioidentical testosterone.

“Assessing the impact of LPCN 1144 treatment on liver fat changes in hypogonadal men with confirmed fatty liver would enable us to understand the underappreciated association between hypogonadism and nonalcoholic fatty liver disease,” Mahesh Patel, PhD, chairman, president and CEO of Lipocine, said in the release. Additionally, the outcome from this clinical study will be an important foundation for designing future clinical studies of LPCN 1144 for the treatment for NAFLD/NASH.”

The researchers enrolled 36 patients and expect complete study results in the first quarter of 2019.

Reference: www.lipocine.com